Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides …

Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2; Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete …